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Abstract
Introduction The role of macrophages in tumor progression has
generated contradictory evidence. We had previously
demonstrated the ability of peritoneal macrophages from LMM3
murine mammary adenocarcinoma-bearing mice (TMps) to
increase the angiogenicity of LMM3 tumor cells, mainly through
polyamine synthesis. Here we investigate the ability of the
parasympathetic nervous system to modulate angiogenesis
induced by TMps through the activation of the muscarinic
acetylcholine receptor (mAchR).
Methods Peritoneal macrophages from female BALB/c mice
bearing a 7-day LMM3 tumor were inoculated intradermally (3 ×
105 cells per site) into syngeneic mice. Before inoculation, TMps
were stimulated with the muscarinic agonist carbachol in the
absence or presence of different muscarinic antagonists or
enzyme inhibitors. Angiogenesis was evaluated by counting
vessels per square millimeter of skin. The expression of mAchR,
arginase and cyclo-oxygenase (COX) isoforms was analyzed by
Western blotting. Arginase and COX activities were evaluated
by urea and prostaglandin E2 (PGE2) production, respectively.
Results TMps, which stimulate neovascularization, express
functional mAchR, because carbachol-treated TMps potently
increased new blood vessels formation. This response was
completely blocked by preincubating TMps with pirenzepine
and 4-diphenylacetoxy-N-methylpiperidine (4-DAMP), M1 and
M3  receptor antagonists, and partly by the M2  receptor
antagonist methoctramine. M1 receptor activation by carbachol
in TMps triggers neovascularization through arginase products
because  Nω-hydroxy-L-arginine reversed the agonist action.
Preincubation of TMps with methoctramine partly prevented
carbachol-stimulated urea formation. In addition, COX-derived
liberation of PGE2 is responsible for the promotion of TMps
angiogenic activity by M3 receptor. We also detected a higher
expression of vascular endothelial growth factor (VEGF) in
TMps than in macrophages from normal mice. Carbachol
significantly increased VEGF expression in TMps, and this effect
was totally reversed by methoctramine and pirenzepine.
Arginase and COX inhibitors partly decreased VEGF derived
from TMps.
Conclusion TMps themselves induce a potent angiogenic
response that is augmented by carbachol action. mAchR
activation triggers arginine metabolism, PGE2 synthesis and
VEGF production, promoting neovascularization.
Introduction
Malignant tumors contain macrophages (Mps) as a major com-
ponent of the host leukocytic infiltrate, and the role of Mps in
tumor progression has generated contradictory evidence [1].
It has been recognized that Mps can act either as negative reg-
ulators by achieving tumor cytotoxicity or as positive regulators
by promoting tumor growth. Neovascularization, an essential
step in tumor progression and metastasis development, can
COX = cyclo-oxygenase; 4-DAMP = 4-diphenylacetoxy-N-methylpiperidine; FCS = fetal calf serum; IL = interleukin; kDa = kilodaltons; mAchR = mus-
carinic acetylcholine receptor; MEM = minimal essential medium; Mps = macrophages; NBT/BCIP = nitro blue tetrazolium/5-bromo-4-chloroindol-3-
yl phosphate; NMps = peritoneal macrophages from normal mice; NOHA = Nω-hydroxy-L-arginine; PBS = phosphate-buffered saline; PGE2 = pros-
taglandin E2; RIA = radio-immunoassay; TBST = Tris-buffered saline containing Tween 20; TMps = peritoneal macrophages from LMM3 murine mam-
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be modulated by the presence of Mps in the tumor microenvi-
ronment. Angiogenic stimuli can proceed from tumor cells
and/or immune cells such as lymphocytes and Mps. We have
previously demonstrated the ability Mps from tumor-bearing
mice to exacerbate the angiogenic response elicited by LMM3
tumor cells (derived from a murine mammary adenocarci-
noma), confirmed by CD31 positivity at the angiogenic site [2].
There are several molecules, such as nitrogen metabolites,
prostaglandins, vascular endothelial growth factor (VEGF),
fibroblast growth factor and placental growth factor, that exert
proangiogenic functions [3]. Less knowledge is available
about the autonomic regulation of tumor neovascularization.
Here we investigate the role of the parasympathetic nervous
system on the angiogenic activity exerted by peritoneal Mps
from 7-day LMM3 mammary-tumor-bearing mice (TMps) by
studying the expression and function of muscarinic acetylcho-
line receptors (mAchRs) in new blood vessel formation
induced by TMps.
Materials and methods
Animals and tumor cell line
BALB/c mice (females 8 to 12 weeks old) from our Animal
Care Division were used. Animal care was provided in accord-
ance with the procedure outlined in the Guide for Care and
Use of Laboratory Animals (NIH, 1986 edition). The tumor cell
line LMM3 had previously been obtained from a spontaneous
syngeneic mammary adenocarcinoma MM3 [4]. LMM3 cells
were maintained as monolayers at 37°C in 5% CO2 in MEM
supplemented with 5% FCS. Cells were detached with
trypsin; only cell suspensions with more than 90% viability
(assessed by Trypan blue) were used. Tumor-bearing mice
were obtained by subcutaneous inoculation into the flank of 4
× 105 LMM3 cells.
Purification of peritoneal macrophages
Resident peritoneal cells from normal mice and tumor-bearing
mice were obtained by washing the peritoneal cavity previ-
ously inoculated with 5 ml of MEM supplemented with 10%
FCS. The adherent Mps population from normal mice (NMps)
and from 7-day tumor-bearing mice (TMps) were purified by
adhesion to plastic for 2 hours. After being washed twice with
PBS, adherent cells were scraped and resuspended in culture
medium. Cell viability was assessed by the Trypan blue exclu-
sion test; only suspensions with more than 95% viability were
used.
Angiogenesis assay
Mps and tumor cell-induced angiogenesis was quantified with
an in vivo bioassay described previously [5]. In brief, tumor cell
suspensions were prepared by detaching and washing LMM3
cells twice with fresh MEM. Cell concentration was adjusted
to 3 × 106cells/ml and female normal mice were inoculated
intradermally in both flanks with 3 × 105 LMM3 cells, NMps or
TMps in a total volume of 0.1 ml of MEM with a drop of Trypan
blue to localize the site of inoculation. Before inoculation, Mps
were treated for 1 hour with carbachol (100 nM) in the
absence or presence of 1 µM atropine, 1 µM pirenzepine, 1
µM methoctramine, 1 µM 4-diphenylacetoxy-N-methylpiperid-
ine (4-DAMP), 100 µM Nω-hydroxy-L-arginine (NOHA), 1 µM
indomethacin or 10 µM NS-398. Cells were washed before
inoculation. On day 5, animals were killed with ether, the skin
was carefully separated from the underlying tissues and the
vascular response was observed with a dissecting micro-
scope (Wild) at × 6.4 magnification. The inoculated sites were
photographed and the slides were projected on a reticular
screen to count the number of vessels per mm2 of skin. Angio-
genesis was quantified as vessel density (δ), calculated as the
total number of vessels divided by the total number of squares.
Detection of muscarinic acetylcholine 
receptor subtypes by Western blotting
Purified Mps (106 cells) were lysed at 4°C with 0.5 ml of 0.5%
Nonidet P40, 10 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 50 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 0.1 mM
orthovanadate and the following protease inhibitors: 10 µg/ml
aprotinin, 10 µg/ml leupeptin, 5 mM PMSF and 50 µg/ml soy-
bean trypsin inhibitor. Lysates were sonicated for 30 s and
centrifuged at 3,000 r.p.m. for 10 min at 4°C. Supernatants
were centrifuged at 10,000 r.p.m. for 20 min at 4°C. The
resulting supernatants were stored at -80°C. Protein concen-
tration was determined by the Lowry method [6].
Samples were subjected to 7.5% SDS-PAGE minigel electro-
phoresis, with 30 µg of protein in each lane. Standards of
known molecular masses were also seeded. After electro-
phoresis, proteins were transferred to a nitrocellulose mem-
brane (Bio-Rad) and washed with distilled water. The
nitrocellulose strips were blocked in buffer (20 mM Tris-HCl,
500 mM NaCl, 0.05% Tween 20 (TBST) with 5% skimmed
milk) for 1 hour at 20 to -25°C and subsequently incubated
overnight with goat anti-M1, anti-M2 and anti-M3 polyclonal
antibodies (Santa Cruz Biotechnology) diluted 1:100 in TBST.
After several rinses with TBST, strips were incubated with the
second antibody (goat anti-mouse IgG conjugated with alka-
line phosphatase, diluted 1:4,000 in TBST) at 37°C for 1 hour.
Bands were revealed with a mixture of nitro blue tetrazolium
chloride and 5-bromo-4-chloroindol-3-yl phosphate p-toluidine
salt (NBT/BCIP) [7]. Quantification of the bands was per-
formed with a computerized densitometer connected to an
image analyzer (Bio-Rad GS700) and is expressed in optical
density units per mm2.
Arginase activity assay
Arginase activity was determined in cell lysates in accordance
with methods described previously [8]. In brief, 105 cells were
treated or not with 100 nM carbachol in the absence or pres-
ence of 100 µM NOHA, 1 µM atropine, 1 µM pirenzepine, 1
µM methoctramine or 1 µM 4-DAMP. After being washed,
cells were lysed with 0.5 ml of 0.1% Triton X-100, 25 mM Tris-
HCl, pH 7.4, containing 5 mM MnCl2. The enzyme was thenAvailable online http://breast-cancer-research.com/content/7/3/R345
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activated by being heated at 56°C for 10 min. Arginine hydrol-
ysis was performed by incubating 25 µl of the activated lysate
with 25 µl of 0.5 M arginine, pH 9.7, at 37°C for 60 min. The
reaction was stopped in acid medium. Urea concentration was
measured at 540 nm with a microplate reader. Results are
expressed as micromoles of urea per hour per million cells.
Detection of arginase isoforms by Western blotting
Mps were rinsed twice with ice-cold PBS and then scraped
into 300 µl lysis buffer (50 mM Tris-HCl, pH 7.5, 0.1 mM
EDTA, 0.1 mM EGTA, 1 µg/ml leupeptin, 1 µg/ml aprotinin
and 0.1 mM PMSF). Lysis was completed by sonication. Sam-
ples (25 µg) were subjected to 10% SDS-PAGE as described
previously [9-11]. Nitrocellulose membranes were incubated
overnight with a monoclonal anti-mouse arginase I antibody
(BD Transduction Laboratories) or with a rabbit anti-arginase
II antibody (a gift from Dr Masataka Mori). The secondary anti-
body anti-mouse or anti-rabbit IgG conjugated with alkaline
phosphatase was added for 1 hour at 37°C. Proteins were
revealed with NBT/BCIP and quantified by a densitometric
analysis.
Prostaglandin E2 assay
Prostaglandin E2 (PGE2) production by Mps was determined
by RIA as described previously [12]. Purified Mps (2 × 106
cells per sample) were incubated for 1 hour at 37°C in a
Dubnoff bath with carbogen in 1 ml of MEM with or without
100 nM carbachol in the absence or presence of 1 µM atro-
pine, 1 µM methoctramine or 1 µM 4-DAMP, 1 µM indometh-
acin or 10 µM NS-398. After incubation, cells were
centrifuged for 10 min at 200 g and supernatants were frozen
at -80°C until the assay was performed. For PGE2 RIA, 100 µl
samples or standards were incubated for 30 min with 500 µl
of rabbit anti-PGE2 antiserum (Sigma) at 4°C. Then 5 pg of
[3H]PGE2 (specific radioactivity 154 Ci/mmol; New England
Nuclear) was added to each tube. All dilutions were performed
in 0.01 M PBS, pH 7.4, containing 0.1% BSA and 0.1%
sodium azide. After incubation, a dextran-coated charcoal sus-
pension was added to separate the bound and free fractions.
The supernatants were removed from each tube and scintilla-
tion solution (Optiphase Hisafe 3; Wallac) was added to
determine the amount of radioactivity present. Results are
expressed in picograms per 105 cells.
Detection of cyclo-oxygenase (COX) isoforms by 
Western blotting
Purified Mps were washed twice in cold PBS and then resus-
pended in 300 µl of lysis buffer (20 mM Tris-HCl, 1 mM EDTA,
10 µg/ml leupeptin, 2 µg/ml aprotinin, 10 µg/ml dithiotreitol,
100 µg/ml soybean trypsin inhibitor, 1 mg/ml benzamidine).
After 1 hour, lysates were centrifuged at 5,000 r.p.m. for 10
min. The resulting supernatants were stored at -80°C. Protein
concentration was determined by the Lowry method [6].
Samples were subjected to 7.5% SDS-PAGE minigel electro-
phoresis, with 30 µg of protein in each lane. Standards of
known molecular masses were also seeded. After electro-
phoresis, proteins were transferred to a nitrocellulose mem-
brane (Bio-Rad) at 4°C for 18 hours. Membranes were then
washed with distilled water and incubated with blocking solu-
tion (5% skimmed milk in TBST) for 1 hour at 20 to -25°C.
Membranes were incubated with rabbit polyclonal anti-COX-1
or anti-COX-2 antibodies (Cayman Chemical) in Tris-buffered
saline for 90 min at room temperature. Then secondary anti-
rabbit IgG antibody conjugated with alkaline phosphatase was
added for 1 hour at 37°C. Proteins were revealed with NBT/
BCIP and quantified by a densitometric analysis [13].
Detection of VEGF by Western blotting
Production of VEGF was measured in lysates from untreated
TMps or TMps treated with 100 nM carbachol for 1 hour in the
absence or presence of 1 µM atropine, 1 µM pirenzepine, 1
µM methoctramine or 1 µM 4-DAMP or the enzyme inhibitors
100 µM NOHA, 1 µM indomethacin or 10 µM NS-398. Cells
were then cultured without FCS at 37°C for 24 hours in 100
mm Petri dishes. After being washed twice with cold PBS,
TMps were lysed in 10 mM Tris-HCl, pH 8, 1% Triton X-100,
100 mM NaCl, 10 mM EGTA, 10 mM EDTA, with protease
inhibitors (1 mM PMSF, 10 µg/ml leupeptin, 10 µg/ml apro-
tinin). After 1 hour in an ice bath, lysates were centrifuged at
10,000 r.p.m. for 10 min at 4°C. Samples were subjected to
10% SDS-PAGE electrophoresis. Proteins were transferred
to nitrocellulose membranes and, after several rinses with dou-
bly distilled water, were blocked with 5% skimmed fat milk in
TBST buffer. The primary antibody (goat polyclonal anti-VEGF;
Santa Cruz Biotechnology) was added for 18 hours, and the
secondary antibody anti-goat IgG conjugated with alkaline
phosphatase was added for 1 hour at 37°C. Proteins were
detected with NBT/BCIP and quantified by densitometric
analysis [13,14].
Drugs
All drugs were purchased from Sigma-Aldrich unless other-
wise stated. Solutions were prepared fresh daily.
Statistics
Results are given as means ± SEM for at least three independ-
ent experiments. The statistical significance of differences
between groups was analyzed by analysis of variance, Tukey's
modified t-test or the Mann–Whitney test, using the STAT
PRIMER program; P < 0.05 was considered to be statistically
significant.
Results
Carbachol stimulates angiogenesis induced by TMps
We have reported previously that a small number of TMps (2
× 103 to 2 × 104 cells) from 7-day LMM3 tumor-bearing mice
were unable to induce an angiogenic response in syngeneic
mice. The vessel density (δ) of mice inoculated with TMps (δ =Breast Cancer Research    Vol 7 No 3    de la Torre et al.
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1.70 ± 0.15) was not significantly different from that observed
in normal skin (δ = 1.65 ± 0.20). In larger numbers (3 × 105),
TMps elicit positive angiogenesis (δ = 2.84 ± 0.06), similar to
that observed with the same number of LMM3 tumor cells (δ
= 2.91 ± 0.38). The addition of 100 nM carbachol increased
the neovascularization induced by TMps by 112% (Table 1).
The participation of mAchR was confirmed by blunting the car-
bachol action with 1 µM atropine. Peritoneal NMps were una-
ble to induce angiogenesis: the neovascular response (δ =
1.86 ± 0.55) was similar to that observed in normal skin. The
addition of carbachol, at the same dose, did not modify the
density of blood vessels (δ = 1.80 ± 0.46).
We then investigated the participation of mAchR subtypes in
neovascularization induced by TMps. As shown in Table 1,
blockade of M1 or M3 receptors with 1 µM pirenzepine or 4-
DAMP, respectively, completely abolished the stimulatory
effect of carbachol on angiogenesis, whereas preincubation
with 1 µM methoctramine (an M2 antagonist) partly prevented
the carbachol action.
Arginase and COX products are involved in 
angiogenesis induced by TMps
Table 2 summarizes results indicating that preincubating
TMps with 100 µM NOHA, 1 µM indomethacin or 10 µM NS-
398 significantly blunted carbachol-stimulated angiogenesis,
demonstrating the participation of arginase and COX in this
effect.
We have previously reported that arginase I and II were con-
stitutively expressed in Mps, and their expression and activity
were upregulated in TMps in comparison with NMps. Our
present results indicate that carbachol, at the same dose that
triggers neovascularization, increases urea formation (Fig. 1).
This overproduction was completely reversed by NOHA (100
µM), an enzyme-specific inhibitor of arginase. mAchR activa-
tion was also blunted by 1 µM atropine or with 1 µM piren-
zepine, indicating a relation between M1 receptor subtype
activation and arginase as its effector enzyme. It is also shown
in Fig. 1 that the M2 selective antagonist methoctramine partly
blunted the action of carbachol. Preincubation of TMps with 4-
DAMP did not modify the action of carbachol on urea forma-
tion (78 ± 7 µmol/h per 106 cells). Western blotting therefore
shows the presence of M1 and M2 receptor proteins in the
membrane-enriched fraction of TMps (Fig. 1).
Table 1
Participation of mAchR subtypes in angiogenesis induced by TMps
Treatment Angiogenic response (vessels/mm2) n
None 2.33 ± 0.07 5
CARB 4.98 ± 0.40** 5
AT + CARB 2.57 ± 0.25 5
PIR + CARB 2.49 ± 0.63 4
MET + CARB 3.35 ± 0.17* 5
4-DAMP + CARB 2.64 ± 0.48 6
Peritoneal macrophages (3 × 105) from 7-day LMM3 tumor-bearing mice (TMps) untreated or stimulated with carbachol (CARB; 100 nM) in the 
absence or presence of 1 µM atropine (AT), pirenzepine (PIR), methoctramine (MET) or 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) were 
inoculated intradermally into normal mice to evaluate the angiogenic response. **P < 0.0001, *P < 0.05 compared with untreated TMps (Mann–
Whitney test). n, number of sites evaluated. Results are means ± SEM for three experiments.
Table 2
Participation of arginase and COX in angiogenesis induced by TMps
Treatment Angiogenic response (vessels/mm2) n
None 2.34 ± 0.06 5
CARB 4.96 ± 0.41* 5
NOHA + CARB 2.4 ± 0.6 4
INDO + CARB 1.9 ± 0.92 8
NS-398 + CARB 1.3 ± 0.31 5
Peritoneal macrophages (3 × 105) from 7-day LMM3 tumor-bearing mice (TMps) stimulated with carbachol (CARB; 100 nM) in the absence or 
presence of Nω-hydroxy-L-arginine (NOHA; 100 µM), indomethacin (INDO; 1 µM) or NS-398 (10 µM) were inoculated intradermally into normal 
mice to evaluate the angiogenic response. *P < 0.001 compared with control (without treatment) (Mann–Whitney test). n, number of sites 
evaluated. Results are means ± SEM for three experiments.Available online http://breast-cancer-research.com/content/7/3/R345
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Prostaglandins are important mediators in tumor progression
because they promote tumor growth and immunosuppress
tumor hosts. Here we show that 100 nM carbachol markedly
increased the liberation of PGE2 by TMps (Fig. 2). This stimu-
latory action was inhibited by preincubating cells with 1 µM
indomethacin or with 10 µM NS-398, a non-selective COX
inhibitor and a COX-2-selective inhibitor, respectively. In addi-
tion, we observed that M3 receptor subtype is involved in car-
bachol-induced PGE2 liberation: not only did 1 µM atropine
blunt the agonist action, but a 1 µM 4-DAMP blockade was
also effective (Fig. 2). Neither pirenzepine (2,879 ± 181 pg of
PGE2/106 cells) nor methoctramine (2,799 ± 197 pg PGE2/
106 cells) modified carbachol-induced PGE2 liberation. We
also detected M3 receptor subtype expression in the TMps
membrane-enriched fraction by Western blotting (Fig. 2).
Participation of VEGF in angiogenesis induced by TMps
Several growth factors and/or cytokines are involved in tumor
angiogenesis. VEGF is the most extensively studied. Here we
measured VEGF expression in lysates of Mps. Western blot
experiments indicate that TMps express larger amounts of
VEGF than NMps do (Fig. 3a). In addition, carbachol signifi-
cantly increases VEGF derived from TMps. Preincubation of
cells with 1 µM methoctramine or pirenzepine blocked the
action of carbachol on VEGF expression, whereas 1 µM 4-
DAMP was ineffective in preventing agonist action. When
TMps were treated with 100 µM NOHA, 10 µM NS-398 or 1
µM indomethacin, VEGF protein expression was decreased by
almost 30% (Fig. 3b).
Discussion
Mps perform multiple functions that are essential in tissue
remodeling, wound healing, inflammation and immunity. These
cells form the major component of the mononuclear leukocyte
population of some solid tumors [1,15]. In the 1980s, Polverini
and Leibovich demonstrated that tumor-associated Mps iso-
lated from 3-methycholanthrene-induced rat fibrosarcoma
were potent stimulators of in vivo neovascularization and
bovine endothelial cell proliferation; depletion of Mps from
tumor cell suspensions significantly decreased their ang-
iogenic potential, suggesting that neovascularization was
mediated in part by Mps [16].
Taking into account the fact that murine mammary adenocar-
cinomas arising spontaneously in BABL/c mice in our labora-
tory are poorly infiltrated by Mps, we showed that peritoneal
Mps from 7-day tumor-bearing mice, when present at low con-
centrations, contribute to the enhancement of LMM3 angio-
genesis by providing polyamine precursors to tumor cells [2].
Although the origin of tumor-infiltrating Mps has been dis-
cussed extensively, evidence supports both recruitment from
the circulating pool of monocytes and the proliferation of the
Figure 1
Arginase and muscarinic receptors in TMps Arginase and muscarinic receptors in TMps. Upper panel: macro-
phages from 7-day LMM3 tumor-bearing mice (TMps) were treated with 
carbachol (CARB) (100 nM) in the absence or presence of 100 µM 
Nω-hydroxy-L-arginine (NOHA), 1 µM atropine (AT), pirenzepine (PIR) 
or methoctramine (MET). Arginase activity was measured by urea pro-
duction as µmol/h per 106 cells. Values are means ± SEM for five 
experiments. **P < 0.001, *P < 0.05 compared with basal; NS, not sig-
nificantly different from basal by Tukey's modified t-test. Lower panel: 
Western blot assay to detect arginase isoforms and muscarinic recep-
tors (M) in lysates of TMps. The molecular masses of the bands indi-
cated on the left are coincident with arginase I, II and M1 and M2 
proteins. One representative experiment of three is shown.
Figure 2
Cyclo-oxygenase (COX) muscarinic receptors in TMps Cyclo-oxygenase (COX) muscarinic receptors in TMps. Upper panel: 
macrophages from 7-day LMM3 tumor-bearing mice (TMps) were 
treated with carbachol (CARB) (100 nM) in the absence or presence of 
1 µM indomethacin (INDO) 10 µM NS-398, 1 µM atropine (AT) or 4-
DAMP. COX activity was measured by prostaglandin E2 (PGE2) libera-
tion by TMps as pg/106 cells. Values are means ± SEM for three exper-
iments. *P < 0.001 compared with basal; #P < 0.001 compared with 
CARB; NS, not significantly different from basal by Tukey's modified t-
test. Lower panel: Western blot assay to detect COX isoforms and 
muscarinic receptors (M) in lysates of TMps. Molecular masses of the 
bands indicated on the left are coincident with COX-1, COX-2 and M3 
proteins. One representative experiment of three is shown.Breast Cancer Research    Vol 7 No 3    de la Torre et al.
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local Mps population, and it has recently been discussed that
Mps could become angiogenic in the presence of diverse
stimuli such as growth factors or low oxygen tension as well as
soluble tumor antigens [17,18]. Here we show that peritoneal
TMps, when inoculated in a number equal to that of LMM3
tumor cells, themselves elicit a potent angiogenic response. In
contrast, 'unstimulated' NMps did not promote angiogenesis
in our model. Further investigation is required to determine
whether TMps activation occurs in the host-tumor interface or
can be triggered at distance by soluble cytokines and/or tumor
antigens.
Other authors have shown that the levels and functions of lym-
phocytes, granulocytes, Mps and natural killer cells are under
the regulation of the autonomic nervous system [19]. We
showed that the activation of mAchR in TMps by the choliner-
gic agonist carbachol increases their angiogenic ability. The
participation of muscarinic receptors was demonstrated by
preincubating cells with the non-selective muscarinic antago-
nist atropine. Angiogenesis is now considered an important
step during inflammation and cancer, and it might be neces-
sary as a local, protective response against invasion by patho-
gens and the proliferation of transformed cells. It is also
important in tumor growth and metastasis. The nervous system
reflexively regulates the inflammatory response and it has been
recently documented that acetylcholine, the principal vagal
neurotransmitter, significantly attenuates the release of
cytokines (tumor necrosis factor, IL-1, IL-6 and IL-18, but not
the anti-inflammatory cytokine IL-10) in lipopolysaccharide-
stimulated human macrophage cultures [20]. These anti-
inflammatory actions are generally related to nicotinic receptor
stimulation [21]. In our model, mAchR stimulation seems to be
promoting pro-inflammatory actions by stimulating angiogen-
esis induced by TMps. It remains to be tested whether the acti-
vation of nicotinic receptors in TMps might be exerting anti-
inflammatory actions.
M1, M2 and M3 antagonists decreased the carbachol stimula-
tion of neovascularization induced by TMps, showing a collab-
orative activation of different mAchR subtypes in the
neovascular response. It has recently been documented that
different mAchR activation controls different functions in dis-
tinct systems simultaneously. The activation of M1 and M3
receptors by carbachol induces pigment granule dispersion in
isolated retinal pigment epithelium from bluegill. Carbachol-
induced pigment granule dispersion is blocked by the mus-
carinic antagonist atropine, by the M1 antagonist pirenzepine
and by the M3 antagonist 4-DAMP [22]. We also showed that
the activation of M1, M2 and M3 receptors by carbachol is
involved in the proliferation of two different murine mammary
adenocarcinoma cell lines, LM3 and LM2 [23].
The carbachol stimulation of angiogenesis induced by TMps
occurs by the signaling of M1 to arginase, because pirenzepine
totally blocked the carbachol stimulation of urea production.
Arginase I and II are overexpressed in TMps in comparison
with NMps and are involved in the positive modulation by
TMps of angiogenesis induced by LMM3 mammary tumor
cells [2]. We were the first to report that carbachol was able
to stimulate the proliferation of tumor cells by arginine metab-
olism through arginase linked to M1 receptors in LM2 cells,
derived from M2 murine mammary adenocarcinoma [23].
We also observed that methoctramine partly blunted carba-
chol-stimulated vascularization and urea formation, indicating
that M2 receptors are also involved in this effect. We have pre-
viously documented a collaborative action of M2 and M3 recep-
tor activation by carbachol, which increases amylase secretion
Figure 3
Western blot assay to detect vascular endothelial growth factor (VEGF) expression Western blot assay to detect vascular endothelial growth factor (VEGF) expression. (a) Expression in normal macrophages (NMps) and macro-
phages from 7-day LMM3 tumor-bearing mice (TMps). (b) TMps were treated with carbachol (CARB) (100 nM) in the absence or presence of 1 µM 
pirenzepine (PIR), methoctramine (MET) or 4-DAMP. Lane C, control (TMps without treatment). Bands were quantified in optical density units per 
square millimeter (OD/mm2). The molecular mass indicated at the left corresponds to the VEGF isoform detected. One representative experiment of 
three is shown.Available online http://breast-cancer-research.com/content/7/3/R345
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in lipopolysaccharide-inflamed salivary glands by stimulating
PGE2  liberation [7]. We are therefore reporting that the
expression and function of M1 and M2 receptors are involved in
the control of angiogenesis induced by TMps, by stimulating
polyamine synthesis in these cells.
The tumor microenvironment is rich in inflammatory cytokines,
growth factors and chemokines, but generally poor in
cytokines associated with a sustained immune antitumor
response. It is now accepted that tumor-associated Mps pro-
duce soluble mediators that contribute to tumor progression.
Our results indicate that the parasympathetic nervous system
positively modulates neovascularization induced by TMps by
stimulating M3  receptors and PGE2  liberation. Because
indomethacin and NS-398 blunted the carbachol action on
PGE2  synthesis, the COX-1 and COX-2 isoenzymes are
involved in angiogenesis induced by TMps. In particular, COX-
2 protein expression is highly upregulated in TMps in compar-
ison with NMps (data not shown). Several authors have stated
that there is a role of COX-2 expression and function not only
in tumors but also in immune cells from the host [14,18,25].
The overproduction of this prostanoid could be responsible for
an autocrine loop that also promotes immunosuppression of
the host.
Previous results indicate that activation of G-protein-coupled
receptors encoded by Kaposi's sarcoma-associated herpesvi-
rus could be increasing VEGF expression and promoting an
angiogenic response that characterizes Kaposi's sarcoma
lesions [26]. In support of this view, we observed that stimula-
tion of mAchR in TMps by carbachol increased the 45 kDa iso-
form of VEGF. This effect is linked to activation of the M2 and
M1 receptors, which in turn promote the arginine metabolic
pathway through arginase. We have previously observed that
the arginase pathway is involved in the angiogenic response
induced by LMM3 cells derived from a murine mammary ade-
nocarcinoma. These cells, which exert a potent angiogenic
response quantitatively similar to that induced by TMps, also
produce significant amounts of VEGF [13]. Our results show
that VEGF production by TMps depends partly on arginase
metabolism because NOHA decreases VEGF production.
Pretreatment of cells with COX inhibitors also diminished
VEGF derived from TMps. In this way, the expression of COX-
1 and COX-2 and their product PGE2 has been shown to be
promoters of angiogenesis by modulating the synthesis of var-
ious factors, including VEGF [13,27]. It must be taken into
account that the stimulation of VEGF expression by COX-
derived PGE2  in TMps is independent of M3  receptor
activation.
Conclusion
Here we propose a new mechanism involved in angiogenesis
induced by peritoneal TMps through mAchR activation sus-
tained by the formation of arginase products and PGE2, which
could be acting as promoters of the stimulation by VEGF of
endothelial cell proliferation, vessel sprouting and organization
during tumor progression or metastasis.
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